The B.1.351 variant first detected in South Africa and identified in the United States this week could drive the country's Covid-19 death toll up to 654,000 by May 1.
Data from Novavax's clinical trial showed that its vaccine is only 49% effective against the South African variant, raising concerns about SARS-CoV-2's resistance.